Who are 4basebio?

4basebio is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems.

The company offers application specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines. These solutions help partners accelerate proof-of-concept studies and reach clinical milestones more efficiently, while maintaining the highest standards of safety and quality.

With a focus on innovation, flexibility, and precision, 4basebio equips biopharma and academic partners with the tools to unlock the full potential of genetic medicine.

4basebio (AIM: 4BB) is an innovation driven biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform.

The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.